Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer

被引:49
作者
Jones, Robert P. [1 ,2 ]
Hamann, Susanne [3 ]
Malik, Hassan Z. [2 ]
Fenwick, Stephen W. [2 ]
Poston, Graeme J. [2 ]
Folprecht, Gunnar [3 ]
机构
[1] Univ Liverpool, Inst Translat Med, Sch Canc Studies, Liverpool L69 3GA, Merseyside, England
[2] Aintree Univ Hosp NHS Fdn Trust, Liverpool Hepatobiliary Unit, Liverpool L9 7AL, Merseyside, England
[3] Univ Hosp Carl Gustav Carus, Univ Canc Ctr, Dresden, Germany
关键词
Liver; Colorectal; Metastases; Surgery; Resection; Chemotherapy; RECIST; PHASE-III TRIAL; 1ST-LINE TREATMENT; ONLY METASTASES; NEOADJUVANT CHEMOTHERAPY; INFUSIONAL FLUOROURACIL; HEPATIC METASTASES; PLUS BEVACIZUMAB; FOLINIC ACID; OXALIPLATIN; IRINOTECAN;
D O I
10.1016/j.ejca.2014.02.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Aims: Long-term survival has been demonstrated for patients with irresectable colorectal liver metastases who are brought to resection by chemotherapy. However, it remains unclear whether improved long-term outcome seen with modern therapies translates to increased rates of secondary resection and whether response rates correlate with rates of secondary liver resection. Methods: A systematic review of literature published between January 1998 and September 2013 was performed. Phase II/III trials were included if they reported the rate of objective response and the rate of secondary resection of initially irresectable metastases. For the phase III trials, the ratio between response and resection rates within the trials was investigated as well as the correlation for both parameters in all trials. Results: Twenty-five studies were identified. Response rate demonstrated a strong correlation with rates of secondary resection (R-2 = 0.44, p = 0.008). Ratios of response/resection between both arms of 10 randomised control trials (RCTs) were calculated to control for selection bias, and showed that in a randomised setting response rates correlate with increased rates of secondary resection in an intra-trial comparison (R-2 = 0.87, p = 0.002). Linear regression analysis demonstrated a significant difference between studies where criteria for resectability were defined (median 39.5%), and those where it was not (median 11%) (p = 0.006). Conclusion: There is a clear correlation between radiological response and rates of secondary resection, with studies that define resectability achieving much higher rates. All trials investigating first line treatment in patients with metastatic colorectal cancer should have criteria for resection, with conversion to secondary resection as a defined study end-point. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1590 / 1601
页数:12
相关论文
共 57 条
[1]
Regional treatment of metastasis: surgery of colorectal liver metastases [J].
Adam, R ;
Vinet, E .
ANNALS OF ONCOLOGY, 2004, 15 :103-106
[2]
The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus [J].
Adam, Rene ;
De Gramont, Aimery ;
Figueras, Joan ;
Guthrie, Ashley ;
Kokudo, Norihiro ;
Kunstlinger, Francis ;
Loyer, Evelyne ;
Poston, Graeme ;
Rougier, Philippe ;
Rubbia-Brandt, Laura ;
Sobrero, Alberto ;
Tabernero, Josep ;
Teh, Catherine ;
Van Cutsem, Eric .
ONCOLOGIST, 2012, 17 (10) :1225-1239
[3]
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study [J].
Alberts, SR ;
Horvath, WL ;
Stcrnfeld, WC ;
Goldberg, RM ;
Mahoney, MR ;
Dakhil, SR ;
Levitt, R ;
Rowland, K ;
Nair, S ;
Sargent, DJ ;
Donohue, JH .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9243-9249
[4]
[Anonymous], ANN ONCOL S8
[5]
[Anonymous], ASCO ANN M P
[6]
[Anonymous], INT J CLIN ONCOL
[7]
[Anonymous], J CLIN ONCOL
[8]
[Anonymous], J CLIN ONCOL S34
[9]
[Anonymous], ANN ONCOL S5
[10]
A phase II experience with neoadjuvant irinotecan (CPT-II), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases [J].
Bathe, Oliver F. ;
Ernst, Scott ;
Sutherland, Francis R. ;
Dixon, Elijah ;
Butts, Charles ;
Bigam, David ;
Holland, David ;
Porter, Geoffrey A. ;
Koppel, Jennifer ;
Dowden, Scot .
BMC CANCER, 2009, 9